About Second Sight
Second Sight is a publicly listed company based in Los Angeles (United States) founded in 2000. Implantable visual prosthetics for blind individuals are developed and provided. Second Sight has raised $52.3 million across 23 funding rounds from investors including NIH and HHS. The company has 14 employees. Second Sight has completed 1 acquisition, including Nano Precision Medical. Its chief executive, as recorded, is Adam Mendelsohn. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its competitors include Kodiak Sciences, Eyedaptic and iScience Interventional; 3 of its 3 listed competitors have raised funding.
Company details
Provider of implantable visual prosthetics for blind individuals. The flagship product, Argus II Retinal Prosthesis System is an FDA and CE-approved device targeted for patients with severe to profound retinitis pigmentosa. Includes a miniature video camera housed in the patients glasses, a patient-worn computer where data is processed and transformed into instructions transmitted wirelessly to an antenna in the retinal implant. The implant emits electrical pulses which create perceptions of patterns of light. Patients learn to interpret these visual patterns with their retinal implant. It is also developing the Visual Cortical Prosthesis, Orion for blinds due to preventable or treatable conditions.
- Headquarters Los Angeles, United States
- Employees 14
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website secondsight.com
- Total Equity Funding$52.3M (USD)
in 23 rounds
- Latest Funding Round$1.1M (USD), Grant
Jul 2022
- InvestorsNIH
& 1 more
- Employee Count14
- Investments & Acquisitions
Funding Insights of Second Sight
Second Sight has successfully raised a total of $52.3M across 23 strategic funding rounds. The most recent funding activity was a Grant round of $1.1 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $52.3M
- Total Rounds 23
- Last Round Grant — $1.1M
- First Round $8.41M
(Jul 2000)
- Investors Count 2
Latest 10 of 23 funding rounds of Second Sight with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Second Sight
Second Sight has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Second Sight
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Second Sight
9 people are tracked at Second Sight (4 in leadership, 5 in board & advisors); the tracked headcount is 14.
| Name | Role | Group |
|---|---|---|
Adam Mendelsohn | CEO | Leadership |
Matt Pfeffer | Acting CEO | Leadership |
Edward Randolph | VP of Operations | Leadership |
Jessy Dorn | VP Clinical and Scientific Affairs | Leadership |
Dean Baker | Director | Board & advisors |
Aaron Mendelsohn | Director | Board & advisors |
Will McGuire | Director | Board & advisors |
Alexandra Larson | Director | Board & advisors |
Gregg G. Williams | Chairman | Board & advisors |
Complete people profiles for Second Sight
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Second Sight
Second Sight has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Nano Precision Medical.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Titanium capsule to provide constant rate delivery of therapeutic | nanoprecisionmedical.com | Emeryville, United States | 2009 | Feb 2022 | •••• |
Complete acquisition details for Second Sight
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Second Sight
5 dated milestones of Second Sight across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Second Sight is founded.
- Funding First funding round of $8.4M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Nano Precision Medical.
- Funding Latest funding round, Grant, of $1.1M.
Competitors of Second Sight
Second Sight has 3 listed competitors in our database, 3 of them funded. They include Kodiak Sciences, Eyedaptic and iScience Interventional.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kodiak.com | 2009 | Palo Alto, United States | $35.84M | 112 | Therapeutics for retinal diseases are developed by the company. | |
| eyedaptic.com | 2016 | Laguna Niguel, United States | $1.42M | A wearable augmented reality vision assistance solution | ||
| iscienceinterventional.com | 1999 | Menlo Park, United States | $36.68M | Microcatheter and imaging technologies for ophthalmic procedures are developed. |
Detailed competitors of Second Sight
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Second Sight
Websites that share an audience with Second Sight (secondsight.com).
Websites whose visitors overlap most with Second Sight. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
gulfmedical.com | gulfmedical.com | 100% | #8,833,242 | – |
Top companies in Ophthalmology
3 companies that operate in the same segment as Second Sight (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Second Sight
Complete news archive for Second Sight
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Second Sight
Second Sight was founded in 2000.
Second Sight is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Adam Mendelsohn is the CEO of Second Sight, as recorded in our data.
Second Sight is a funded company, having raised a total of $52.3M across 23 funding rounds to date. The company's 1st funding round was a Series B of $10M, raised on Jul 2000.
Second Sight has 14 employees.
Provider of implantable visual prosthetics for blind individuals. The flagship product, Argus II Retinal Prosthesis System is an FDA and CE-approved device targeted for patients with severe to profound retinitis pigmentosa. Includes a miniature video camera housed in the patients glasses, a patient-worn computer where data is processed and transformed into instructions transmitted wirelessly to an antenna in the retinal implant. The implant emits electrical pulses which create perceptions of patterns of light. Patients learn to interpret these visual patterns with their retinal implant. It is also developing the Visual Cortical Prosthesis, Orion for blinds due to preventable or treatable conditions.
Second Sight's top competitors include Kodiak Sciences, iScience Interventional and Eyedaptic.
Second Sight has made 1 acquisition, including Nano Precision Medical.